Physician profile
Kathleen M Jablonski
NPI 1871816108
$2,658.96
in general payments reported to CMS, 2019-2025
9 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Oncology (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $263).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $263 · 2022: $1,062 · 2023: $316 · 2024: $511 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,166 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.59 |
| Education | $167.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $1,082.06 | 2021-2022 | |
| Janssen Biotech, INC. | $977.06 | 2023-2025 | Tecvayli, Rybrevant, Darzalex |
| Astrazeneca Pharmaceuticals Lp | $220.73 | 2024 | Enhertu |
| Seagen INC. | $112.90 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.99 | 2021 | |
| Astellas Pharma US INC | $93.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $42.79 | 2025 | |
| Celgene Corporation | $15.97 | 2021 | |
| Myovant Sciences INC. | $14.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Jablonski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.